HSHiroshi Sunaga

Hiroshi Sunaga

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hiroshi Sunaga has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Kaoru Suzuki

    Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

    4 shared publications
  • Kentaro Yamakawa

    Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

    4 shared publications
  • Shoichi Uezono

    Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

    4 shared publications
  • Yusuke Miyazaki

    Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

    4 shared publications
  • Ichiro Kondo

    Affiliation Department of Anesthesiology, The Jikei University School of Medicine, Tokyo, Japan

    2 shared publications
  • Shotaro Hobo

    Department of Anesthesiology, Mitsui Memorial Hospital, Tokyo, Japan

    2 shared publications

Latest Publications

  • Sugammadex Versus Neostigmine for Bariatric Surgery: Methodological Concerns

    by Yusuke Miyazaki, Kaoru Suzuki, Kentaro Yamakawa, Hiroshi Sunaga


  • Open Access

    General anesthesia with remimazolam in a patient with clinically suspected malignant hyperthermia

    by Keita Uchiyama, Hiroshi Sunaga, Nobuyuki Katori, Shoichi Uezono


  • Open Access

    Intravenous infusion of rocuronium bromide prolongs emergence from propofol anesthesia in rats

    by Kaoru Suzuki, Hiroshi Sunaga, Kentaro Yamakawa, Yoshifumi Suga, Ichiro Kondo, Tsunehisa Tsubokawa, Shoichi Uezono

    Background: Neuromuscular blocking agents induce muscle paralysis via the prevention of synaptic transmission at the neuromuscular junction and may have additional effects at other sites of action. With regard to potential effects of neuromuscular blocking agents on the central nervous system, a definitive view has not been established. We investigated whether intravenous infusion of rocuronium bromide affects the emergence from propofol anesthesia. Methods: Using an in vivo rat model, we performed propofol infusion for 60 minutes, along with rocuronium bromide at various infusion rates or normal saline. Sugammadex or normal saline was injected at the end of the infusion period, and we evaluated the time to emergence from propofol anesthesia. We also examined the neuromuscular blocking, circulatory, and respiratory properties of propofol infusion along with rocuronium bromide infusion to ascertain possible factors affecting emergence. Results: Intravenous infusion of rocuronium bromide dose-dependently increased the time to emergence from propofol anesthesia. Sugammadex administered after propofol infusion not containing rocuronium bromide did not affect the time to emergence. Mean arterial pressure, heart rate, partial pressures of oxygen and carbon dioxide, and pH were not affected by rocuronium bromide infusion. Neuromuscular blockade induced by rocuronium bromide, even at the greatest infusion rate in the emergence experiment, was rapidly antagonized by sugammadex. Conclusions: These results suggest that intravenous infusion of rocuronium bromide dose-dependently delays the emergence from propofol anesthesia in rats. Future studies, such as detection of rocuronium in the cerebrospinal fluid or central nervous system, electrophysiologic studies, microinjection of sugammadex into the brain, etc., are necessary to determine the mechanism of this effect.


  • Open Access

    Effect of intravenous infusion of rocuronium on emergence from propofol anesthesia in rats

    by Kaoru Suzuki, Hiroshi Sunaga, Kentaro Yamakawa, Yoshifumi Suga, Ichiro Kondo, Tsunehisa Tsubokawa, Shoichi Uezono

    Background: Central nervous system effects of neuromuscular blocking agents have been indicated in some case reports. We investigated whether intravenous (IV) infusion of rocuronium affects emergence from propofol anesthesia in rats. Methods: We used Sprague Dawley rats. Propofol infusion was initiated with a bolus of 15 mg/kg and continued at a rate of 40 mg/kg/h. For the rocuronium group (n = 18), rocuronium was administered as an initial IV bolus of 5 mg/kg followed by continuous infusion at a rate of 250, 500, or 1000 μg/kg/min along with propofol infusion. Infusion was continued for 60 min, and sugammadex (32 mg/kg) was injected at the end of infusion. In a separate group of rats (n = 12), normal saline was administered along with propofol infusion. After continuous infusion for 60 min, normal saline or sugammadex (32 mg/kg) was injected. The time to emergence from propofol anesthesia was evaluated. To ascertain possible factors affecting emergence, the neuromuscular blocking, circulatory, and respiratory properties of IV rocuronium infusion at 1000 μg/kg/min were assessed (n = 18). Results: The time to emergence from propofol anesthesia was 239 ± 94 s after simultaneous infusion of normal saline without rocuronium and was 346 ± 78, 518 ± 134, and 638 ± 219 s after IV infusion of rocuronium at 250, 500, and 1000 μg/kg/min, respectively. The simultaneous IV infusion of rocuronium dose-dependently increased the time to emergence (ρ = 0.624; p = 0.006). Sugammadex alone did not delay emergence (280 ± 60 s; p = 0.39). Neuromuscular blockade induced by rocuronium at 1000 μg/kg/min was completely antagonized at 99 ± 21 s by sugammadex (32 mg/kg). Mean arterial pressure, heart rate, partial pressures of oxygen and carbon dioxide, and pH were not affected by rocuronium infusion. Conclusions: Our results show that IV infusion of rocuronium delays the emergence from propofol anesthesia in rats, despite the complete recovery from neuromuscular blockade by sugammadex. The use of neuromuscular blocking agents in neonates or patients with cerebrovascular diseases, whose blood-brain barrier might be immature or disrupted, should be carefully considered.

  • Incidence of Anaphylaxis Associated With Sugammadex

    by Yusuke Miyazaki, Hiroshi Sunaga, Kotaro Kida, Shotaro Hobo, Nobuyoshi Inoue, Masayuki Muto, Shoichi Uezono

    We retrospectively investigated the incidence of potential sugammadex-induced anaphylaxis at a single center in Japan over a period of 3 years. The overall incidence of intraoperative hypersensitivity reaction was 0.22% (95% confidence interval [CI], 0.17%–0.29%), and the incidence of anaphylaxis was 0.059% (95% CI, 0.032%–0.10%). The total number of patients who received sugammadex during the study period was 15,479, and the incidence of anaphylaxis associated with sugammadex was 0.039% (n = 6; 95% CI, 0.014%–0.084%). This result implies that the incidence of sugammadex-associated anaphylaxis could be as high as that for succinylcholine or rocuronium. A prospective study, including testing for identification of cause, is necessary to confirm the exact incidence of sugammadex-induced anaphylaxis; however, the present finding calls attention to this potential.


  • Pancuronium enhances isoflurane anesthesia in rats via inhibition of cerebral nicotinic acetylcholine receptors

    by Yusuke Miyazaki, Hiroshi Sunaga, Shotaro Hobo, Kazuko Miyano, Shoichi Uezono

    Purpose This study was conducted to elucidate the mechanism of enhancement of volatile anesthetics by neuromuscular blocking agents in rats and to consider the relevance of this enhancement to clinical anesthesia. Methods Male Sprague–Dawley rats were used. After confirming a movement in response to tail clamping under 1.1 % isoflurane anesthesia, response was determined when the tail clamp was applied at several points after microinjection of pancuronium into the lateral ventricle. Arousal responses to microinjection of nicotine into the lateral ventricle were assessed with or without pretreatment with intraventricular pancuronium. The intravenous 50 % effective dose (ED50) and 95 % effective dose (ED95) for neuromuscular blockade with pancuronium administered in a cumulative fashion at 1.1 % isoflurane were calculated. Results Intraventricular pancuronium dose-dependently reduced the response to tail clamping, and the dose required to show immobilization of 50 % of rats (intraventricular ED50) was 1.62 µg/kg. Pretreatment with pancuronium at 6 µg/kg significantly reduced the effect of awakening by nicotine under isoflurane anesthesia (P = 0.044). The intravenous ED50 and ED95 for neuromuscular blockade were 63 µg/kg (90 % confidence interval [CI] 52–75 µg/kg) and 133 µg/kg (90 % CI 109–158 µg/kg), respectively. The ratio of intraventricular ED50 to intravenous ED50 was 0.026. Conclusion Pancuronium microinjection into the lateral ventricle dose-dependently enhances the depth of isoflurane anesthesia, which might be caused by inhibition of neuronal nicotinic acetylcholine receptor transmission in the cerebrum. Intravenous injection of pancuronium at high doses might increase the cerebrospinal concentration to a level at which an effect can be observed.


  • Expression of Syk is associated with nasal polyp in patients with allergic rhinitis

    by Yuki Hamajima, Sigeharu Fujieda, Hiroshi Sunaga, Takechiyo Yamada, Kazuho Moribe, Nobuhiro Watanabe, Shingo Murakami


  • The Efficacy of Intratracheal Administration of Vecuronium in Rats, Compared with Intravenous and Intramuscular Administration

    by Hiroshi Sunaga, Masahisa Kaneko, Yoshikiyo Amaki

    To investigate the suitability of the intratracheal (IT) route as an alternative route for the administration of vecuronium, we compared the pharmacodynamic parameters for neuromuscular block in three groups of rats given vecuronium via the IT, IM, and IV routes. We also examined the pharmacokinetics of vecuronium in the three groups. The doses for the IT, IV, and IM groups were set at 1.50, 0.300, and 2.25 mg/kg, respectively. The onset of action in the IT group (127 +/- 17 s) was significantly earlier than that in the IM group (267 +/- 62 s), and significantly later than that in the IV group (18 +/- 7 s) (P < 0.05 by analysis of variance and the Tukey-Kramer analysis). The duration of action in the IT group (794 +/- 162 s) was significantly longer than that in the IV group (93 +/- 30 s) but not significantly different from that in the IM group (743 +/- 131 s). The recovery index in the IT group (134 +/- 30 s) was significantly shorter than that in the IM group (222 +/- 47 s) and significantly longer than that in the IV group (32 +/- 12 s). Although IT administration of vecuronium is still slower than IV administration, it appears to be more advantageous as compared with IM administration, given the more rapid absorption and faster onset of action.